When will Vigabatrin be released?

In 2009, the U.S. Food and Drug Administration (FDA) approved Vigabatrin for the first time to be marketed under the trade name Sabril. Since then, several generic versions of the drug have become available, including one sold under the brand name Vigadrone. It is currently approved by the European Medicines Agency (EMA) and sold under the trade name Kigabeq. The original drug of Vigabatrin has not yet been launched in the country, so it is not included in medical insurance. Vigabatrin is available in two dosage forms, a 500 mg tablet for the add-on treatment of adults with refractory complex partial seizures (CPS) and a 500 mg powder package as an oral solution for infants with seizures (IS).